Research programme: anticancer monoclonal antibodies - Genmab/ScancellAlternative Names: Human monoclonal antibodies programme - Genmab/Scancell
Latest Information Update: 04 Apr 2008
At a glance
- Originator Genmab; Scancell
- Class Monoclonal antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Oct 2001 Preclinical development for Cancer in England (Parenteral)
- 16 Oct 2001 Preclinical development for Cancer in Denmark (Parenteral)